Shifting from cytology to HPV testing for cervical cancer screening in Canada

KEY POINTS
Infection with high-risk strains of the human papillomavirus (HPV) is a known prerequisite for developing cervical cancer.[1][1] Soon, a test for high-risk strains of HPV will replace the Papanicolaou (Pap) test for routine cervical cancer screening in Canada. Unlike the Pap test, which

Related Keywords

Australia ,United States ,Canada ,Netherlands ,United Kingdom ,Canadian ,American ,British ,Emily Delpero ,Papanicolaou Pap ,Amanda Selk ,Society Of Gynecologic Oncology Canada ,Canadian Agency For Drugs ,Society Of Canadian Colposcopists ,Technologies In Health ,American Cancer Society ,Canadian Agency ,Cervical Cancer ,British Columbia ,Canadian Colposcopists ,Gynecologic Oncology ,Searchlight Pharma ,Open Access ,Creative Commons Attribution ,